Pemphigus is a group of autoimmune blistering diseases of the skin and mucous membranes that are characterized histologically by intraepidermal blisters due to the loss of cell- 
Pemphigus as an Autoimmune Disease Against Desmosomal Cadherin
The term pemphigus stems from the Greek pemphix meaning blister or bubble and describes a group of chronic blistering skin diseases in which autoantibodies are directed against the cell surface of keratinocytes, resulting in the loss of cell-cell adhesion of keratino cytes through a process called acantholysis.1 Pemphigus can be divided into three major forms; pemphigus vul garis, pemphigus foliaceus, and paraneoplastic pemphi gus (Table 1) .
In pemphigus vulgaris, essentially all patients have mucosal membrane erosions and more than half of them also have skin blisters and erosions. The blisters of pemphigus vulgaris develop in the deeper part of the epidermis, just above the basal cell layer. In pemphigus foliaceus, patients have only cutaneous involvement without mucosal lesions and the splits occur in the su perficial part of the epidermis, mostly at the granular layer. Pemphigus vegetans is a vegetative variant of pemphigus vulgaris, and pemphigus erythematosus and fogo selvagem are localized and endemic variants of pemphigus erythematosus, respectively. Paraneoplastic pemphigus was more recently recognized as a disease distinct from the classic forms of pemphigus .2 Patients with paraneoplastic pemphigus have a known or occult associated neoplasm, usually of lymphoid tissue . Painful severe oral and conjunctival erosions are a prominent feature of paraneoplastic pemphigus .
The hallmark of pemphigus is the finding of IgG autoantibodies against the cell surface of keratinocytes . 3 The pemphigus autoantibodies found in patients' sera play a primary pathogenic role in inducing the loss of (Table 1) .4-8 Molecular cloning of cDNA encoding pemphigus anti gens indicates that both these molecules are members of the cadherin supergene family.9,10 Pemphigus folia ceus and vulgaris antigens are termed desmogleinl (Dsg1) and desmoglein 3 (Dsg3), respectively. Thus, pemphigus was discovered to be an anti-cadherin auto immune disease. The basic pathophysiology of pemphi gus is that autoantibodies inhibit the adhesive function of desmogleins and lead to the loss of cell-cell adhesion of keratinocytes with resultant blister formation.
Compelling evidence has accumulated that IgG autoantibodies against Dsg1 and Dsg3 are pathogenic and play a primary role in inducing the blister forma tion in pemphigus. IgG that is affinity-purified from pemphigus vulgaris sera on the extracellular domain of Dsg3 can cause suprabasilar acantholysis, the typical histologic finding of pemphigus vulgaris, when injected into neonatal mice.11 Furthermore, when anti-Dsg3 IgG is immunoadsorbed with the extracellular domains of Dsg3 from pemphigus vulgaris sera, those sera no longer have the pathogenic activity to cause blisters in neonatal mice.12 Similarly, immunoadsorption of pem phigus foliaceus sera with the extracellular domains of Dsgl eliminates the pathogenic activity of those sera and anti-Dsgl IgG bound on the column can cause su perficial blisters in neonatal mice. 13 
Desmoglein Compensation Theory as an Explanation for Localization of Blisters
The disruption of desmoglein-dependent cell adhe sion by autoantibodies is the basic pathophysiology in blister formation of pemphigus, but the clinical spec trum of pemphigus is more complex than this. Splits associated with pemphigus foliaceus occur in the su perficial layer of the epidermis, while those of pemphi gus vulgaris occur deep in the epidermis. Oral erosions are developed in patients with pemphigus vulgaris, but not in patients with pemphigus foliaceus. Some patients with pemphigus vulgaris have only oral involvement, but others have extensive lesions on both skin and mu cous membranes. These complex clinical features of pemphigus are explained logically by the desmoglein compensation theory: i.e. Dsg1 and Dsg3 compensates for their adhesive function when they are coexpressed in the same cell (Fig. 1 ). [14] [15] [16] When pemphigus vulgaris is divided into two sub groups, the mucosal dominant type which is de monstrated by mucosal lesions with minimal skin involvement and the mucocutaneous type which is demonstrated by extensive skin blisters and erosions in addition to mucosal involvement, each subtype of pemphigus has its own anti-desmoglein antibody profile (Table 1) . Patients with pemphigus foliaceus have only anti-Dsgl IgG autoantibodies.
Patients with the mucosal dominant type of pemphigus vulgaris have only anti-Dsg3 IgG autoantibodies, while the mucocu taneous type of pemphigus vulgaris has both anti-Dsg3 and anti-Dsgl IgG autoantibodies. 17 The intraepithelial expression pattern of Dsg1 and Dsg3 are different be tween skin and the mucous membranes. In the skin, Dsgl is expressed throughout the epidermis, but more intensely in the superficial layers, while Dsg3 is expressed in the lower part of the epidermis, mainly in the basal and parabasal layers. 18 In contrast, in the mucous membranes, Dsgl and Dsg3 are expressed throughout the squamous mucosal epithelia, but Dsgl is expressed at a much lower level than Dsg3.14 When sera contain only anti-Dsgl IgG which inter feres with the function of Dsgl, those sera cause blisters only in the superficial epidermis because that is the only area in which Dsgl is present without coexpression of Dsg3 (Fig. 1A) . In the unaffected deep epidermis , the presence of Dsg3 compensates for the loss of func tion of Dsgl. Although the anti-Dsgl IgG binds to the mucosa, no blisters are formed because of the co expression of Dsg3. Thus, sera containing only anti -Dsg1 IgG cause superficial blisters in the skin without mucosal involvement as seen in patients with pemphi gus foliaceus. When sera contain only anti-Dsg3 IgG, those sera do not effectively cause blisters in the skin because the co-expressed Dsg1 compensates for Fig. 1 Explanation of the sites of blisters in pemphigus by the desmoglein compensation theory. The triangles represent the distribution of desmogleinl (Dsg1) and desmoglein3 (Dsg3) in the skin and mucous membranes. Pemphigus foliaceus sera contain only anti-Dsg1 IgG and cause superficial blisters in the skin because Dsg3 functionally compensates for the impaired Dsg1 in the lower part of the epidermis, while these sera do not cause blisters in the mucous membrane because cell-cell adhesion is mainly mediated by Dsg3 (A). Sera containing only anti -Dsg3 IgG cause no or only limited blisters in the skin because Dsg1 compensates for the loss of the Dsg3-mediated adhesion, whereas those sera induce separation in the mucous membrane where the low expression of Dsg1 will not compensate for the loss of the Dsg3-mediated adhesion (B). When sera contain both anti-Dsg1 and anti-Dsg3 IgG, the function of both Dsgs are compromised and blisters occur both in the skin and mucous membranes (C).
the impaired function of Dsg3, resulting in no or only limited skin blisters (Fig. 1B) . In contrast, in mucous membranes, Dsg1 cannot compensate for the impaired Dsg3 function because of its low expression. Therefore, sera containing only anti-Dsg3 IgG cause oral erosions without apparent skin involvement as seen in patients with the mucosal dominant type of pemphigus vulgaris. When sera contain both anti-Dsgl and anti-Dsg3 IgG, they interfere with the function of both Dsg1 and Dsg3, resulting in extensive blisters and erosions in the skin as well as the mucous membranes, as seen in patients with the mucocutaneous type of pemphigus vulgaris (Fig.  1C) . It is not clear why splits occur just above the basal layer instead of the whole keratinocyte falling apart, it is however speculated that the cell-cell adhesion be tween the basal and parabasal layers might be weaker than the other parts of the epidermis because there are Staphylococcal scalded skin syndrome (SSSS) is a generalized, confluent, superficially exfoliative disease that is caused by the exfoliative toxin (ET, also known as epidermolytic toxin, epidermolysin, and exfoliatin) of Staphylococcus aureus. The splits occur in the super ficial epidermis, at the level of the granular layer. ET has two major serotypes: A and B (ETA and ETB, respectively). In SSSS, S. aureus is present at a distant focus, such as the pharynx, nose, ear, or conjunctiva, and ET produced by S. aureus enters the circulation and causes exfoliation at remote sites, while in bullous impetigo, a localized form of SSSS, S. aureus is present in the lesions. In 1970, Melish and Glasgow identified the toxin responsible by injecting newborn mice with broth cultures of S. aureus isolated from patients with SSSS, resulting in blister formation.20 However, its mode of action in vivo remained an unanswered ques tion for more than three decades.
One day, we realized that SSSS and pemphigus foliaceus share many similar features. Both diseases involve only the skin, and not mucous membranes or other tissues. The histology of both diseases shows superficial epidermal separation where Dsg3 is not co expressed. Pathology textbooks actually say that the histology of both diseases is indistinguishable. When IgG from PF is injected into neonatal mice, the mice develop blisters. When ET is injected into neonatal mice, the mice also develop blisters. The histology in both mice is essentially identical. These similarities caused us to consider whether the molecular mecha nism of blister formation in SSSS was actually similar to that in PF, and we started to investigate the fate of Dsg1 after ET treatment. 21 We first stained Dsg1 and Dsg3 in mouse skin one hour after injecting ETA into neonatal mice. ETA caused substantial changes in Dsg1 staining, which was much less intense on keratinocyte cell surfaces, while there was no apparent change in Dsg3 staining. We next examined whether Dsg1 is degraded after ETA treatment. We performed an immunoblot analysis for Dsg1, Dsg3, and E-cadherin on extracts of skin from the mice that developed blisters. The 160-kDa Dsg1 was degraded into a peptide of approximately 113 kDa, while there was no degradation of Dsg3 or E-cadherin. To demonstrate direct proteolysis of the extracellular domain of Dsg1 by ETA, we incubated a soluble recombinant form of the extracellular domains of Dsg1 and Dsg3 with ETA in vitro (Fig. 2) . ETA cleaved the recombinant mouse and human Dsg1 in a dose dependent fashion, while ETA did not cleave Dsg3 at all. Combined, these findings indicate that ETA specifi cally recognizes and cleaves the extracellular domain of Fig. 2 In vitro digestion of the recombinant extracellular domains of human Dsg1 by exfoliative toxin. Dsg1 and Dsg3 extracellular domains produced in baculovirus were incubated with or without exfoliative toxin A (ET) and subjected to immunoblotting to visualize Dsg1 and Dsg3. The toxin cleaved the extracellular domain of Dsg1, but not that of Dsg3. The arrowhead and arrow indicate intact recombinant Dsg1 and the cleaved product, respectively. both mouse and human Dsg1. Subsequently, we also demonstrated that ETB, another major serotype of ET, specifically cleaved Dsg1 in a manner identical to ETA. 22 These findings provide an important framework to understand the molecular mechanism of blister forma tion in these diseases, as well as cell-to-cell adhesion of keratinocytes in the epidermis. By bringing dermato logical tools to bear on our observations we were thus able to clarify of the molecular mechanism of an exfo liative toxin, which had remained unsolved for three decades after its identification.
A Novel Autoimmune Mouse Model Using the Autoantigen Knockout Mouse
To investigate the pathophysiological mechanisms and to develop therapeutic strategies, animal disease models have been playing important roles in the study of various conditions including autoimmune diseases. To examine the cellular mechanisms of autoantibody production in pemphigus, specimens from patients are naturally the best clinical material, but it is not easy to obtain sufficient amounts with proper controls. To overcome this problem an active disease model is required. The conventional approach to develop an autoimmune mouse model is forced immunization of autoantigens in various strains of mice (Fig. 3A) . How ever, this approach is empirical and immune responses are largely dependent on the strains of mice or types of adjuvant used. Furthermore, any autoimmune reaction in those mice may be transient, unlike that found in patients, and the immune system is systemically stimu lated.
The major difficulty in the development of an auto immune reaction in mice is because of the self-tolerance factor inherent in homeostasis, which prevents the im mune system from reacting destructively against self components. When lymphocytes are exposed to self components during the development of the immune system, auto-reacting lymphocytes are eliminated or inactivated. We have taken a novel approach to over come this problem. Because self-tolerance is a technical barrier to the development of autoimmune mouse models we thought of generating a condition where self-tolerance is not established in an antigen-specific way. If it were possible to remove the antigen during the development of the immune system, or if were not present from the start, tolerance against the removed or absent molecule would not be acquired (Fig. 3B) . In the autoantigen knockout mouse, lymphocytes are not exposed to the defective gene product, and self tolerance against that particular autoantigen is not established. Upon immunization with the autoantigen, the autoantigen knockout mice should elicit an immune reaction against the autoantigen. However, in the im munized knockout mice, the antigen-antibody reac tion is not expected because the mice lack the target antigen. Therefore, lymphocytes from the immunized autoantigen knockout mice are adoptively transferred to wild type mice that express the autoantigen. The transferred lymphocytes from the autoantigen knock out mice should be persistently stimulated by the endo genous autoantigen in the recipient mice and should therefore produce antibodies against the autoantigen with resultant phenotypes of the human disease.
Pemphigus Mouse Model with Persistent Pathogenic Antibody Production
To develop an active disease mouse model for pem phigus vulgaris, we took this novel approach of using autoantigen knockout mice, in the case of pemphi gus vulgaris, Dsg3-/-mice.23 When we immunized Dsg3-/-mice with mouse recombinant Dsg3, anti-Dsg3 IgG was indeed produced. These sera were able to bind to the cell surfaces of living cultured mouse keratino cytes, indicating that the anti-Dsg3 IgG produced in Dsg3-/-mice is capable of binding to the native Dsg3 on living keratinocytes. In contrast, sera from Dsg3+/ -littermates or wild type mice failed to bind to the sur face of living keratinocytes. These findings confirmed that Dsg3-/-mice and mice expressing Dsg3 have a clear difference in their ability to produce anti-Dsg3 IgG that can bind to the native Dsg3.24 Despite the production of anti-Dsg3 IgG, no auto immune reaction is expected in the immunized Dsg3-/ -mice because they lack the target antigen. To allow the anti-Dsg3 IgG to be exposed to the antigen, we isolated splenocytes from the immunized Dsg3-/-mice and transferred them into Rag-2-/-immunodeficient mice that do express Dsg3. Rag-2-/-mice have no mature T or B cells due to the inability to rearrange T cell receptors or immunoglobulin genes and thus are unable to produce antibodies or reject the transferred spleno cytes. Circulating anti-Dsg3 IgG was detected in the sera of recipient Rag-2-/-mice as early as day 4 after the transfer of Dsg3-/-splenocytes , and its titer in creased rapidly without further boosting by recombi nant Dsg3, and reached a plateau around day 21 . The circulating anti-Dsg3 IgG was detected for as long as 6 autoimmune disease months or more. No significant reactivity against Dsg1, another desmosomal cadherin targeted in pemphigus foliaceus, was observed in these recipient mice during this period. In contrast, no circulating anti-Dsg3 IgG was detected in Rag-2-/-mice given Dsg3+/-spleno cytes. The persistent anti-Dsg3 IgG production indi cates that endogenous Dsg3 in the recipient mice stimulated the transferred Dsg3-specific lymphocytes from the immunized Dsg3-/-mice in vivo.
In recipient mice with Dsg3-/-splenocytes, in vivo IgG deposition was found on keratinocyte cell surfaces in stratified squamous epithelia, including the skin and oral and esophageal mucous membranes, just as seen in patients with pemphigus vulgaris (Fig. 4A) . In these mice, no IgG deposition was found in other tissues, including heart, lung, liver, kidney, stomach, and small and large intestines. These IgG binding sites corre spond to the known tissue distribution of Dsg3. Histo logical examination of the recipient mice revealed an intraepithelial loss of cell-cell adhesion just above the basal layers, i.e., suprabasilar acantholysis, in the buccal mucosa, hard palate, oropharyngeal areas, and the up per part of the esophagus, just as in human patients (Fig. 4B) . These oral erosions likely inhibited food in take, resulting in the weight loss (Fig. 4C) . Some of the recipient mice developed crusted erosions on the skin around the snout, an area that is normally traumatized by scratching (Fig. 4D) . Close histological examination revealed that the recipient mice with Dsg3-/-spleno cytes also exhibited eosinophilic spongiosis which is often found in patients with early lesions. 25 We also observed patchy hair loss in the recipient mice with Dsg3-/-splenocytes. This hair loss phenotype also persisted for over 6 months. Skin biopsy showed intense IgG deposition on the cell surface of keratinocytes surrounding the telogen hair club. Cleft formation was observed between the cells surrounding the telogen club and the basal layer of the outer root sheath epi thelium. In contrast, no phenotypic or pathological changes were observed in recipient mice with Dsg3+/ -splenocytes. These results indicate that the Rag-2-/ -recipient mice given immunized Dsg3-/-splenocytes developed clinical, histologic and immunopathologic phenotypes similar to those of patients with pemphigus vulgaris.24 A major hurdle in developing animal models of autoimmune diseases has been overcoming the self tolerance component of the homeostatic system . We circumvented this problem by immunizing autoantigen knockout mice with the autoantigen, then transferring their splenocytes to Rag-2-/-mice that expressed the autoantigen. Although this model does not reflect the actual triggers of autoimmune diseases , it does provide a means to investigate the roles of T and B lymphocytes in perpetuating autoantibody production in the auto immune response. 26 We are also attempting to isolate a panel of monoclonal anti-Dsg3 IgG antibodies from pemphigus model mice, and investigate their patho genic strength to clarify what factor(s) determines the severity of the disease. In addition, this active animal model should be beneficial for evaluating various ther apeutic strategies that could modulate the autoimmune response. Finally, our approach is widely applicable to various antibody-mediated and T cell-mediated auto immune diseases, unless the relevant autoantigen knockout mice are embryonicaly lethal or show gross abnormalities in their immune systems.
